PHARMACOKINETIC DYNAMIC RELATIONSHIPS

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation

Correspondence Professor Shigeo Horinaka, Department of Cardiology and Nephrology, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi 321-0293, Japan. Tel.: +81 2 8286 1111, extension 2735; Fax: +81 2 8286 1596; E-mail: horinaka@dokkyomed.ac.jp

Received 19 February 2017; Revised 17 August 2017; Accepted 1 September 2017

Shigeo Horinaka*, Rie Sugawara, Yutaka Yonezawa and Toshihiko Ishimitsu

Department of Cardiology and Nephrology, Dokkyo Medical University, Tochigi, Japan

*Principal investigator.

Keywords nonvalvular atrial fibrillation, plasma concentration, rivaroxaban, tissue factor pathway inhibitor, trough steady state

AIMS
The aim of the present study was to demonstrate evidence of reduced thrombin generation at the trough plasma rivaroxaban concentration.

METHODS
A single-centre, prospective, nonrandomized, drug-intervention, self-controlled study was conducted in 51 anticoagulation therapy-naïve patients with nonvalvular atrial fibrillation. Plasma rivaroxaban concentration was measured by liquid chromatography tandem mass spectrometry (LC–MS/MS) and the anti-factor Xa chromogenic assay. Partial thrombin time (PT), protein C activity, and protein S antigen, prothrombin fragment 1 + 2 (F1 + 2), D-dimer, thrombomodulin (TM), thrombin–antithrombin complex (TAT), plasminogen activator inhibitor-1 (PAI-1) and tissue factor pathway inhibitor (TFPI) levels were also measured at the trough steady state after 4 weeks of rivaroxaban treatment and compared with baseline.

RESULTS
Plasma concentrations obtained by the LC–MS/MS and anti-Xa assays were correlated (r = 0.841, P < 0.001). The mean concentration of rivaroxaban at the trough steady state was 23.6 ng ml\(^{-1}\), at which F1 + 2, TAT and D-dimer had decreased from the baseline values (P < 0.0001, P = 0.029 and P < 0.005, respectively). PT was prolonged (+0.59 s, P < 0.0001). TFPI increased from baseline to the trough steady state in the first to third quartile groups (+0.79 pg ml\(^{-1}\), P = 0.048). By contrast, PAI-1, protein C activity, protein S antigen and TM remained within the normal range at the trough steady state.

CONCLUSIONS
Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation.
Introduction

Once-daily oral administration of rivaroxaban, a direct factor Xa inhibitor, demonstrates an equal or superior prophylactic effect on cerebral infarction and systemic embolism compared with adjusted-dose warfarin treatment. This was shown in the Rivaroxaban-Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, in which the target international normalized ratio (INR) was 2.0-3.0 and the mean percentage of time in the therapeutic range (TTR) was 55.2% [1, 2]. It was also demonstrated in the J ROCKET AF trial, with adjustment of the standard dosage from 20 mg in the ROCKET AF trial to 15 mg for Japanese patients using pharmacokinetic modelling data [3] and a lower anticoagulation target in elderly people in the Japanese guideline [4], with a target INR of 2.0-3.0 in patients aged <70 years and a TTR of 51.8%; the reduced INR was 1.6-2.6 in patients aged ≥70 years and the TTR was 74% [5]. This effect of rivaroxaban this was not found to be associated with increased haemorrhagic events in patients with nonvalvular atrial fibrillation (NVAF) in the ROCKET AF and J ROCKET AF trials. Currently, the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban are available for clinical use. Although the half-life of the serum concentration of these drugs is almost 12 h and the serum concentrations display peaks and troughs, the numbers of administrations and dosages are not necessarily consistent [6]. With regard to rivaroxaban, phase II trials in venous thromboembolism [oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic proximal deep vein thrombosis (ODIXa-DVT)] [7] revealed that efficacy did not differ among once-daily (40 mg), twice- (10, 20 and 30 mg) daily and enoxaparin followed by a vitamin K antagonist, and safety was superior with once-daily dosing to twice-daily dosing or to enoxaparin followed by a vitamin K antagonist for 3 months. Similarly, the Einstein-DVT dose-ranging study [8] demonstrated that efficacy and safety did not differ between three different dosing groups (20, 30 or 40 mg once daily) and a low-molecular-weight heparin or vitamin K antagonist group after 3 months of treatment. Thus, the phase III large-scale ROCKET AF worldwide randomized trial was conducted using the standard fixed dose of 20 mg rivaroxaban once daily in patients with NVAF.

Thrombin generation may be almost completely inhibited at the maximum concentration of rivaroxaban in terms of the peak phase. By contrast, the rivaroxaban plasma concentration drops nearly zero at 20-24 h after administration, in terms of the trough steady state [3, 6]. Thus, the mechanism whereby once-daily administration of rivaroxaban is effective at the trough phase remains to be clarified. Yasaka [9] explained this mechanism on the basis of the hypothesis of activation and/or maintenance of physiological anticoagulation factors such as tissue factor pathway inhibitor, antithrombin, protein C, protein S and the fibrinolytic system during trough phase. However, changes in coagulation, anticoagulation and fibrinolytic markers have never been evaluated in the trough steady state after rivaroxaban treatment in anticoagulation therapy-naïve patients with NVAF.

The present study was conducted to test the hypothesis that the residual plasma rivaroxaban at the trough steady state plays a role in reducing thrombin generation, which also involves tissue factor pathway inhibitor (TFPI) at the trough steady state compared with those before treatment in anticoagulation therapy-naïve patients.

Patients and methods

Study design and patient selection

This was a single-centre, prospective, nonrandomized, drug-intervention, self-controlled study aimed at identification of the antithrombin effect of the trough steady state of rivaroxaban treatment in anticoagulation therapy-naïve patients. Newly diagnosed patients with NVAF, aged >20 years and referred to Dokkyo Medical University Hospital to initiate oral anticoagulant treatment with rivaroxaban, were considered eligible for the study. Patients who met any of the following criteria were excluded from the study: less than 6 months after the onset of acute myocardial infarction, unstable angina or arteriosclerosis obliterans; within 6 months after surgery; having acute phase congestive heart failure, as defined by the National Institute for Health and Care Excellence (NICE) guideline [10]; taking medication with dual-antiplatelet therapy; having concomitant chronic kidney disease [creatinine clearance (CCr) (Cockcroft-Gault) <30 ml min⁻¹], having a malignant tumour, rheumatic disease, uncontrollable hypertension or infection; or considered ineligible to participate by the attending physician. All patients provided written informed consent, and baseline
Blood sample collection and rivaroxaban dosing
Physicians at our hospital enrolled patients from Monday to Friday. After obtaining informed consent, baseline characteristics and peripheral blood samples were collected between 9:00 AM and 10:00 AM on the enrolment day. Patients were prescribed rivaroxaban from enrollment and took the drug every morning after breakfast between 8:00 AM and 9:00 AM. After at least 4 weeks of treatment, to measure the plasma concentration of rivaroxaban in the trough phase, patients visited our hospital at 8:30 AM before taking the drug in the morning, and peripheral blood samples were collected between 8:30 AM and 9:30 AM. The drug was administered thereafter. Blood samples were divided into a citrate-containing tube and a lithium heparin tube. After centrifugation at 1600 g for 10 min, platelet-poor plasma was collected, and it was quickly frozen and stored at −80°C until measurement of the rivaroxaban concentration. Rivaroxaban dosing was determined by Ccr (Cockcroft–Gault formula). The rivaroxaban dose was 15 mg once daily when Ccr was more than 50 ml min⁻¹, and 10 mg once daily when Ccr was 30–49 ml min⁻¹.

Blood sample assay
Haemostasis, coagulation and physiological anticoagulation markers assay. Partial thrombin time (PT) (normal range: 9.4–12.5 s) was measured using the coagulation turbidity method by HemosIL. RecombiPlasTin 2G (Instrumentation Laboratory, Bedford, MA, USA). Protein C activity (normal range: 64–135%) and protein S antigen levels (normal range: 60–127%) were also determined by the synthetic chromogenic assay and antigenic immunoassay, respectively, using the ACL TOP analyser (Instrumentation Laboratory, Bedford, MA, USA). Prothrombin fragment 1 + 2 (F1 + 2) (normal range: 69–229 pmol l⁻¹) was measured by the enzyme-linked immunosorbent assay (ELISA), using the BEP® III analyser (Siemens Healthcare, Erlangen, Germany). D-dimer (normal range: <0.72 μg ml⁻¹) was measured by enzyme immunoassay using the LPIA ACE DD dimer II on the LPIA-NV7 analyser (LSI Medience Corporation, Tokyo, Japan). TM (normal range: 8.7–22.7 U ml⁻¹) and thrombin–antithrombin complex (TAT) (normal range: <3.0 ng ml⁻¹) were determined by chemiluminescent enzyme immunoassay using STACIA CLEIA TM and STACIA CLEIA TAT, respectively (LSI Medience Corporation). Plasminogen activator inhibitor-1 (PAI-1) (normal range: <50 ng ml⁻¹) was also measured by the chemiluminescent latex agglutination assay using the LPAI tPAI test on the STACIA analyser (LSI Medience Corporation). TFPI levels (normal range: 7.5–41.2 ng ml⁻¹) were measured by the quantitative sandwich ELISA using monoclonal antibody specific for human TFPI (Quantikine® ELISA, Human TAPI Immunoassay, R&D Systems, Inc., Minneapolis, MN, USA). Patients were also divided into quartile groups based on the pretreatment TFPI levels, and the differences (trough TFPI – baseline TFPI) in each group were analysed.

Liquid chromatography tandem mass spectrometry (LC–MS/MS) assay. Plasma concentrations of rivaroxaban were measured by Swiss BioQuant AG (Reinach, Switzerland) using LC–MS/MS validated in accordance with the US Food and Drug Administration guidance for Industry, Bioanalytical Method Validation [11].

Anti-factor Xa chromogenic assay. The anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using rivaroxaban calibrators and controls (STA®-Liquid Anti-Xa with STA®-Rivaroxaban Calibrator and Control, Diagnostica Stago, Asnières, France) calibrated rivaroxaban plasma concentrations, expressed in ng ml⁻¹, and this working range was from 20 ng ml⁻¹ to 500 ng ml⁻¹ [12].

Clinical events
The observation period for the incidence of clinical events was 3 months after administration of rivaroxaban. Stroke, systemic embolism and all bleeding events were included in the clinical events.

Stroke and systemic embolism definitions
Stroke was defined as an abrupt episode of a focal neurological deficit generally in the distribution area of a single brain artery, lasting at least 24 h. Systemic embolism was defined as an abrupt episode of arterial insufficiency associated with clinical or radiological evidence of arterial occlusion. In the presence of atherosclerotic peripheral arterial disease, the diagnosis of embolism required angiographic demonstration of abrupt occlusion.

Definitions of bleeding
Major bleeding was defined according to the International Society on Thrombosis and Haemostasis criteria [13]. Nonmajor bleeding was defined as acute or subacute clinically overt bleeding that did not satisfy the criteria for major bleeding and led to hospital admission for bleeding. When nonmajor or minor bleeding was observed, patients were instructed to visit the hospital the following morning without taking rivaroxaban.

Statistical analysis
The results are presented as mean ± standard deviation or median [the lowest (Q1) – third (Q3) quartiles] for continuous data, and numbers and percentages for categorical data. The data are represented visually by box plots to identify outliers and compare distributions. The primary endpoint was changes in coagulation, anticoagulation and fibrinolysis markers at the trough steady state after 4 weeks of rivaroxaban treatment. Comparison of two groups was tested by the paired t-test or Wilcoxon signed-rank test on the basis of the data distribution with and without normality. Factors that reached significant differences and plasma concentrations were analysed by dosage. The correlation coefficient

Br J Clin Pharmacol (2018) 84:79–87 81
Results

A total of 51 patients were enrolled in the study. The clinical characteristics are shown in Table 1. Mean age, weight, CHADS2, CHA2DS2-VASc scores and CCr were 67.4 ± 11.0 years, 63.7 ± 12.7 kg, 1.33 ± 1.05, 2.43 ± 1.55 and 63.2 ± 18.9 ml min⁻¹, respectively, and 38 patients (75%) were male. Forty-one patients (80%) received rivaroxaban at a dose of 10 mg (20%). When compared by dosage, patients who received rivaroxaban at a dose of 10 mg (10 mg: −0.48 s, P < 0.0001; 15 mg: −0.59 s, P < 0.0001) had significantly older, and had higher CHADS2 and CHA2DS2-VASc scores and lower weight and CCr than those who received 15 mg (Table 1).

Haemostasis and coagulation markers

PT was slightly but significantly prolonged at the trough steady state of rivaroxaban compared with that before treatment [+0.59 s, P < 0.0001 (10 mg: +1.07 s, P = 0.0133; 15 mg: +0.48 s, P < 0.0004); Figure 1A]. F1 + 2 significantly decreased and returned to the normal range at the trough steady state of rivaroxaban compared with that before treatment [−94.2 pg ml⁻¹, P < 0.0001 (10 mg: −57.7 pg ml⁻¹, P = 0.0323; 15 mg: −103.3 pg ml⁻¹, P < 0.0001); Figure 1B]. TAT returned to the normal level at the trough steady state of rivaroxaban compared with that before treatment [−4.7 mg ml⁻¹, P = 0.0285 (10 mg: −1.9, P = 0.0133; 15 mg: −5.4, P = 0.0398); Figure 1C]. D-dimer also declined to the normal level at the trough steady state of rivaroxaban compared with that before treatment [−0.9 μg ml⁻¹, P < 0.0050 (10 mg: −0.7 μg ml⁻¹, P = 0.0505; 15 mg: −0.9 μg ml⁻¹, P = 0.0133); Figure 1D]. The PAI-1 level did not change (Table 2). Thus, there were no significant differences in these values between the two doses.

Physiological anticoagulation markers

Protein C activity, protein S antigen, TM and TFPI levels did not change, but maintained a normal range at the trough steady state of rivaroxaban compared with the values before treatment (Table 2). However, TFPI levels were significantly increased at the trough steady state when the baseline TFPI was at the level of Q1 to Q3 (mean difference = +0.79 pg ml⁻¹, P = 0.048), and TFPI levels were decreased in the upper quartile (Q4) (mean difference = −6.62 μg ml⁻¹, P = 0.032) when patients were divided in quartile groups on the basis of the baseline TFPI levels, as shown in Figure 2.

Plasma rivaroxaban concentrations measured by the LC–MS/MS and anti-factor Xa chromogenic assays at the trough steady state

The mean plasma rivaroxaban concentration measured by the LC–MS/MS assay was 23.6 ± 15.4 ng ml⁻¹ [range: 3.2–74.0 ng ml⁻¹ (Q1: 3.2–12.3; Q2: 12.3–20.8; Q3: 20.8–31.8; Q4: 31.8–74.0); Figure 3]. The plasma concentrations measured by the LC–MS/MS assay did not differ between

Table 1

Baseline clinical characteristics of patients

| Overall (n = 51) | 15 mg OD (n = 41) | 10 mg OD (n = 10) | P value 15 mg vs. 10 mg |
|-----------------|-----------------|-----------------|------------------------|
| Male/female     | 38/13           | 33/8            | 5/5                    | 0.100 |
| Age, years      | 67.4 ± 11.0     | 65.2 ± 10.1     | 76.2 ± 10.3            | 0.004 |
| Congestive heart failure | 18          | 13              | 5                       | 0.474 |
| Hypertension    | 21              | 15              | 6                       | 0.302 |
| Diabetes mellitus | 7              | 7               | 0                       | 0.184 |
| Stroke          | 3               | 2               | 1                       | 0.496 |
| CHADS2 score    | 1.33 ± 1.05     | 1.20 ± 1.03     | 1.90 ± 0.99             | 0.036 |
| CHA2DS2-VASc score | 2.43 ± 1.55 | 2.19 ± 1.45     | 3.40 ± 1.65             | 0.030 |
| Weight          | 63.7 ± 12.7     | 65.8 ± 12.0     | 55.0 ± 12.1             | 0.026 |
| CCr (Cockcroft–Gault; ml min⁻¹) | 63.2 ± 18.9 | 67.3 ± 17.2     | 44.4 ± 16.6             | 0.001 |
| 30–49 ml min⁻¹   | 10              | 0               | 10                      | -       |
| Child–Pugh grade B or C | 0              | 0               | 0                       | -       |

Ccr, creatinine clearance; CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke [double weight]; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years [double weight]; diabetes mellitus, stroke [double weight], vascular disease, 74 > age ≥ 65 years, sex category (female); OD, once daily treatment.
Figure 1

(A) Partial thrombin time at baseline and the trough steady state after rivaroxaban treatment. Box plots are shown; the bottom and top of the box are the first and third quartiles, and the band inside the box is the second quartile (the median). PT, prothrombin time; trough = trough steady state at 4 weeks of rivaroxaban treatment. (B) Prothrombin fragment 1 + 2 at baseline and the trough steady state after rivaroxaban treatment. F1 + 2, prothrombin fragment 1 + 2; trough = trough steady state at 4 weeks of rivaroxaban treatment. (C) Thrombin–antithrombin complex at baseline and the trough steady state after rivaroxaban treatment. TAT, thrombin–antithrombin complex; trough = trough steady state at 4 weeks of rivaroxaban treatment. (D) D-dimer at baseline and the trough steady state on rivaroxaban treatment. Trough = trough steady state at 4 weeks of rivaroxaban treatment.

Table 2

Feedback inhibition markers

| Feedback Inhibition markers | Baseline          | Trough           | P value |
|-----------------------------|-------------------|------------------|---------|
| PAI-1 (ng ml\(^{-1}\))      | 23.50 ± 18.96     | 24.40 ± 17.74    | 0.802   |
| Protein C (%)               | 103.2 ± 19.61     | 103.8 ± 18.88    | 0.533   |
| Protein S (%)               | 92.48 ± 18.67     | 92.44 ± 18.07    | 0.805   |
| TM (FU ml\(^{-1}\))         | 15.33 ± 4.53      | 15.90 ± 3.97     | 0.192   |
| TFPI (pg ml\(^{-1}\))       | 27.25 ± 9.45      | 26.77 ± 8.37     | 0.684   |

Values are presented as mean ± standard deviation.
PAI-1, plasminogen activator inhibitor-1; TM, thrombomodulin; TFPI, tissue factor pathway inhibitor.
By contrast, the plasma rivaroxaban concentration measured by the anti-Xa assay was 28.9 ± 14.3 ng ml$^{-1}$ (range: 7.8–87.0 ng ml$^{-1}$). The plasma concentrations measured by the anti-Xa assay also did not differ between the 10 mg (35.3 ± 23.9 ng ml$^{-1}$; range: 11.4–87.0 ng ml$^{-1}$) and 15 mg (27.2 ± 10.9 ng ml$^{-1}$; range: 7.8–57.2 ng ml$^{-1}$) dosages. However, a significant correlation was observed between plasma concentrations measured by the LC–MS/MS and anti-Xa assays ($r = 0.854$, $P < 0.0001$), and the Bland–Altman analysis revealed that the plasma concentrations measured by the LC–MS/MS assay were significantly lower than those measured by the anti-Xa assay (differences: $-5.67 ± 7.73$ ng ml$^{-1}$; $P < 0.0001$; Figure 4). Thus, the calibrated rivaroxaban plasma concentrations measured by the anti-factor Xa chromogenic assay were slightly overestimated compared with those measured by the LC–MS/MS assay at relatively low concentrations at the trough steady state.

**PT and plasma rivaroxaban concentration measured by the LC–MS/MS assay**

Although PT weakly correlated with plasma concentration measured by the LC–MS/MS assay ($r = 0.448$), it showed high degrees of individual variability. Thus, a normal value of PT cannot be used to exclude the existence of plasma
rivaroxaban, especially in the trough phase, and PT can be used only to obtain a crude estimate.

**Incidence of events**

No events of stroke, systemic embolism or major bleeding were observed in any patients but a few nonmajor haemorrhagic events were observed. One patient (CHADS2 score of 2, CHA2DS2-VASc score of 4) who received rivaroxaban 15 mg and aspirin 100 mg developed haematuria after 4 weeks of treatment, and the trough steady-state plasma concentration of rivaroxaban measured by the LC–MS/MS assay was 74.0 ng ml$^{-1}$. Another patient (CHADS2 score of 1, CHA2DS2-VASc score of 3) who received rivaroxaban 10 mg and had a Child–Pugh score A for liver cirrhosis associated with a reduction in the number of platelets developed progressive subcutaneous haemorrhage after 4 weeks of treatment, and the trough plasma concentration was 16.4 ng ml$^{-1}$. Another patient (CHADS2 score of 1, CHA2DS2-VASc score of 2) who received rivaroxaban 15 mg developed haemostomputum after 4 weeks of treatment, and the trough plasma concentration was 41.7 ng ml$^{-1}$.

**Discussion**

The present study demonstrated that plasma rivaroxaban could be detected at the trough steady state by both the LC–MS/MS assay. Although the residual plasma concentrations were distributed over a wide range, residual rivaroxaban could downregulate and almost completely reduce the process of thrombin generation, which was demonstrated by normalization of F1 + 2, TAT and D-dimer without over-suppression of the feedback inhibition system such as the protein C–TM–thrombin–activated protein C system. TFPI was also upregulated at the trough steady state when the baseline TFPI was included in Q1–Q3, and was downregulated in Q4 if patients were divided into quartiles on the basis of the pretreatment TFPI levels. The overall results showed that PT was slightly yet significantly prolonged in our study.

In the present study, thrombin generation in response to rivaroxaban administration was assessed indirectly by measuring F1 + 2, an indicator of prothrombin activation [15]. TAT is also formed when thrombin cleaves antithrombin to bind with it [16], and a high value of TAT means excessive thrombin generation. D-dimer, which is a very stable coagulation marker, reflects the amount of thrombin formation and endogenous turnover of fibrin as well as activation of fibrinolysis. Anticoagulant therapy significantly suppresses the D-dimer level, which is an independent marker that can predict stroke or systemic embolism, cardiovascular mortality and bleeding [13]. Thus, the present study suggested that rivaroxaban effectively attenuates activation of the haemostatic system, even at the trough steady state, compared with the natural state in patients with NVAF who have never used anticoagulant therapy before.

The mechanism whereby rivaroxaban may play a role to prevent thrombotic events at the trough steady state is under speculation.

Firstly, Perzborn et al. [17] reported that the plasma concentration of rivaroxaban is below the half maximal inhibitory concentration (IC$_{50}$) of 21 nM (9.15 ng ml$^{-1}$) of endogenous human plasma factor Xa activity in an *in vitro* study. Thus, the residual plasma rivaroxaban may exert a persistent anticoagulation action because the mean plasma concentration (23.6 ng ml$^{-1}$) was comparable with the IC$_{50}$ of factor Xa activity in our study. Gerotziafas et al. [18] also reported inhibition of thrombin generation by rivaroxaban with an IC$_{50}$ of 2.1 nM (0.92 ng ml$^{-1}$) using a prothrombin assay of the reconstituted prothrombinase complex on platelets. Rivaroxaban also prolonged the initial phase of thrombin generation (represented by the lag time) after activation of the tissue factor pathway. Levels of approximately 20 nM (8.7 ng ml$^{-1}$) and 10 nM (4.4 ng ml$^{-1}$) of rivaroxaban induced a twofold increase in the lag time of F1 + 2 formation in whole blood, and thrombin generation was also observed in platelet-rich plasma. During the propagation phase of thrombin generation, the IC$_{50}$ values for the rate of F1 + 2 formation in whole blood and thrombin generation in platelet-rich plasma were 60 nM (26.1 ng ml$^{-1}$) and 10 nM (4.4 ng ml$^{-1}$), respectively. In fact, the minimum plasma concentration of rivaroxaban at the trough steady state was 7.3 nM (3.2 ng ml$^{-1}$) in our study. Thus, even at this minimum concentration, rivaroxaban may inhibit thrombin generation and delay the initial and/or propagation phase. Graff et al. [19] also reported that factor Xa activity and endogenous thrombin potential triggered by collagen or tissue factor return to the baseline, but prothrombinase-induced clotting time remained prolonged at 24 h after a single rivaroxaban dose of 5 mg in healthy subjects. These small amounts of rivaroxaban, which had an almost undetectable effect on factor Xa activity, could inhibit prothrombinase-induced thrombin generation via factor Xa. The authors also speculated that active drug remained bound to platelets and maintained the inhibition of thrombin generation at 24 h after once-daily treatment of rivaroxaban at 5 mg, which caused an almost undetectable plasma concentration of rivaroxaban. However, this mechanism seems doubtful because a small amount of rivaroxaban in the plasma could be traced in our study after 24 h of repeated administration of 10 mg or 15 mg of rivaroxaban for 4 weeks in patients with NVAF.

Secondly, the anticoagulation effect of rivaroxaban at the trough steady state may be implemented by maintained physiological anticoagulation factors such as appropriate levels of protein C activity, protein S antigen and TM. Vitamin K is necessary for synthesizing protein C and protein S, which both include a Gla domain. The vitamin K antagonist warfarin prevents the creation of the Gla domain by inhibiting the gamma-carboxylation of glutamic acid. Thus, a vitamin K antagonist causes a decline in protein C activity and protein S levels [20, 21]. By contrast, rivaroxaban did not affect the protein C activity or protein S level. This finding is in agreement with that of a previously published study [22]. TM binds to the excessively produced thrombin, altering its substrate affinity and activating protein C. This pathway is one of the important feedback inhibition mechanisms of the blood coagulation cascade. However, this protein C-TM-thrombin-activated protein C system may not continue to prevent the antithrombotic effects of
rivaroxaban as, in the present study, this system did not change from before to after rivaroxaban treatment.

Thirdly, TFPI is also an anticoagulation protein and a dual inhibitor, binding to the tissue factor/factor VIIa complex to prevent it from acting on the factor IX and factor X substrates, and inhibiting factor Xa directly. Therefore, factor Xa exerts negative feedback on its own production. TFPI is the principal regulator of the initial phase of thrombin generation [23]. Heparin and low-molecular-weight heparin derivatives release TFPI from the vascular endothelium, which may contribute primarily to the antithrombotic effect [24]. Approximately 80–85% of the total body TFPI is associated with the endothelial cell surface and 15–20% is circulating in the plasma, of which 80% is bound to lipoproteins and the rest is in the free form. The free TFPI in the plasma is the physiologically active anticoagulant part of TFPI [25]. TFPI may be ineffective at tissue factor concentrations below the threshold, which is comparable with Q1–Q3. Thus, TFPI may be upregulated after rivaroxaban treatment if the baseline value is in the normal range. This effect also may contribute to the antithrombotic effect of rivaroxaban at the trough steady state.

In the present study, minor haemorrhagic events were observed in a few patients with a relatively high plasma concentration of rivaroxaban and prolongation of PT compared with the mean of all patients in the trough steady state, while patients with an underlying disease prone to haemorrhage were excluded, similarly to previously reports of edoxaban [30]. However, a much larger sample size would be beneficial to confirm this association in a future study.

**Limitations**

Although the present study demonstrated evidence of reduced thrombin generation even at the trough steady state of rivaroxaban, it is not fully understood whether or not this reduced thrombin generation is associated with the prevention of cerebral infarction and systemic embolism. The study did not evaluate the peak concentration of rivaroxaban while this was influencing anticoagulation markers in the trough steady state. However, it was difficult to measure the actual peak concentration as this had a greater individual variability than that of the trough concentration. Although antithrombin was not measured, the antithrombin activity assay based on thrombin inhibition has previously been shown not to be affected by rivaroxaban [31]. To date, it has not been possible to evaluate the pharmacodynamics of rivaroxaban treatment. Other limitations were the small number of patients and short observational period for analysis of clinical events, and the present lack of observation of stroke or embolic events.

**Conclusions**

In conclusion, residual plasma rivaroxaban significantly reduced thrombin generation at the trough steady state, which may play a role in the prevention of thromboembolic events in patients with NVAF.

**Competing Interests**

This study has received research grants from Bayer Yakuhin, Ltd. S.H. has received honoraria for lectures from Bayer Yakuhin, Ltd. There are no other potential conflicts of interest relevant to this article.

**References**

1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91.

2. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013; 2: e000067.

3. Kaneko M, Tanigawa T, Hashizume K, Kajikawa M, Tajiri M, Mueck W. Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet 2013; 28: 321–31.

4. Japanese Circulation Society Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 2010; 74: 2479–500.

5. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J 2012; 76: 2104–11.

6. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625–51.

7. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939); the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007; 116: 180–7.

8. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008; 112: 2242–7.

9. Yasaka M. J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan. Circ J 2012; 76: 2086–7.

10. National Institute for Health and Care Excellence. Acute heart failure: diagnosing and managing. (clinical guideline [CG187]). 2014. Available at https://www.nice.org.uk/guidance/cg187 (last accessed October 2014).
Effect of trough-phase rivaroxaban in NVAF

11 US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for industry, bioanalytical methods validation. 2001. Available at https://www.fda.gov/cder/guidance/index.htm.

12 Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379–87.

13 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3: 692–4.

14 Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2016; 14: 1054–68.

15 Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 2004; 15: 149–56.

16 Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993; 117: 71–7.

17 Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3: 514–21.

18 Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 866–8.

19 Graff J, von Hentig N, Missetlitz J, Cebotar D, Becka M, Breddin HK, et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398–407.

20 Malhotra OP, Nesheim ME, Mann KG. The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. J Biol Chem 1985; 260: 279–87.

21 Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 1987; 45: 783–90.

22 Hitaka Y, Ogawa M, Zhang B, Goto S, Nagata Y, Morii J, et al. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation. J Cardiol 2016; 68: 529–33.

23 Bajaj MS, Birkoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959–72.

24 van’t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 1997; 272: 4367–77.

25 Kaiser B, Hoppensteadt DH, Fareed J. Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs 1998; 7: 1121–37.

26 van’t Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 1997; 272: 7983–94.

27 Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322–33.

28 Kentsis A, Bradwin G, Miller DT, Trenor CC 3rd. Venous thrombosis associated with gene deletion of tissue factor pathway inhibitor. Am J Hematol 2009; 84: 775–6.

29 Ndonwi M, Girard TJ, Broze GJ Jr. The C-terminus of tissue factor regulates protein C binding, and may be involved in regulation of tissue factor pathway inhibitor. J Biol Chem 1997; 272: 94.

30 Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385: 2288–95.

31 Hillarp A, Baghai E, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133–9.